Mentice Valuation
Is MNTC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MNTC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MNTC (SEK31) is trading below our estimate of fair value (SEK51.35)
Significantly Below Fair Value: MNTC is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MNTC?
Other financial metrics that can be useful for relative valuation.
| What is MNTC's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | SEK 807.98m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.7x |
| Enterprise Value/EBITDA | -1810.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MNTC's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.7x | ||
SYNT SyntheticMR | 12.2x | 18.8% | SEK 1.2b |
PTRK Physitrack | 1.3x | 20.3% | SEK 227.7m |
RAY B RaySearch Laboratories | 4.2x | 10.6% | SEK 4.4b |
MEDHLP Medhelp Care Aktiebolag | 1x | 16.0% | SEK 88.9m |
MNTC Mentice | 2.8x | 18.1% | SEK 792.6m |
Price-To-Sales vs Peers: MNTC is good value based on its Price-To-Sales Ratio (2.8x) compared to the peer average (4.7x).
Price to Earnings Ratio vs Industry
How does MNTC's PE Ratio compare vs other companies in the European Healthcare Services Industry?
Price-To-Sales vs Industry: MNTC is expensive based on its Price-To-Sales Ratio (2.8x) compared to the European Healthcare Services industry average (2.6x).
Price to Sales Ratio vs Fair Ratio
What is MNTC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.9x |
| Fair PS Ratio | 6.1x |
Price-To-Sales vs Fair Ratio: MNTC is good value based on its Price-To-Sales Ratio (2.8x) compared to the estimated Fair Price-To-Sales Ratio (6.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | SEK 31.00 | SEK 47.67 +53.8% | 23.8% | SEK 63.00 | SEK 36.00 | n/a | 3 |
| Jul ’25 | SEK 29.20 | SEK 45.00 +54.1% | 25.7% | SEK 61.00 | SEK 34.00 | n/a | 3 |
| Jun ’25 | SEK 27.00 | SEK 45.00 +66.7% | 25.7% | SEK 61.00 | SEK 34.00 | n/a | 3 |
| May ’25 | SEK 35.60 | SEK 55.33 +55.4% | 14.0% | SEK 65.00 | SEK 46.00 | n/a | 3 |
| Apr ’25 | SEK 33.30 | SEK 55.33 +66.2% | 14.0% | SEK 65.00 | SEK 46.00 | n/a | 3 |
| Mar ’25 | SEK 37.60 | SEK 60.67 +61.3% | 9.0% | SEK 65.00 | SEK 53.00 | n/a | 3 |
| Feb ’25 | SEK 47.70 | SEK 64.67 +35.6% | 5.1% | SEK 67.00 | SEK 60.00 | n/a | 3 |
| Jan ’25 | SEK 47.70 | SEK 67.17 +40.8% | 8.8% | SEK 74.50 | SEK 60.00 | n/a | 3 |
| Dec ’24 | SEK 39.90 | SEK 67.17 +68.3% | 8.8% | SEK 74.50 | SEK 60.00 | n/a | 3 |
| Nov ’24 | SEK 32.60 | SEK 67.17 +106.0% | 8.8% | SEK 74.50 | SEK 60.00 | n/a | 3 |
| Oct ’24 | SEK 32.70 | SEK 67.17 +105.4% | 7.7% | SEK 74.50 | SEK 63.00 | n/a | 3 |
| Sep ’24 | SEK 37.00 | SEK 67.17 +81.5% | 7.7% | SEK 74.50 | SEK 63.00 | n/a | 3 |
| Aug ’24 | SEK 43.50 | SEK 67.17 +54.4% | 7.7% | SEK 74.50 | SEK 63.00 | SEK 33.50 | 3 |
| Jul ’24 | SEK 37.50 | SEK 66.17 +76.4% | 9.6% | SEK 74.50 | SEK 59.00 | SEK 29.20 | 3 |
| Jun ’24 | SEK 41.70 | SEK 66.17 +58.7% | 9.6% | SEK 74.50 | SEK 59.00 | SEK 27.00 | 3 |
| May ’24 | SEK 42.40 | SEK 66.17 +56.1% | 9.6% | SEK 74.50 | SEK 59.00 | SEK 35.60 | 3 |
| Apr ’24 | SEK 37.00 | SEK 64.17 +73.4% | 13.0% | SEK 74.50 | SEK 54.00 | SEK 33.30 | 3 |
| Mar ’24 | SEK 45.80 | SEK 66.17 +44.5% | 13.3% | SEK 74.50 | SEK 54.00 | SEK 37.60 | 3 |
| Feb ’24 | SEK 37.10 | SEK 68.17 +83.7% | 20.7% | SEK 84.50 | SEK 50.00 | SEK 47.70 | 3 |
| Jan ’24 | SEK 37.80 | SEK 79.75 +111.0% | 6.0% | SEK 84.50 | SEK 75.00 | SEK 47.70 | 2 |
| Dec ’23 | SEK 40.80 | SEK 79.75 +95.5% | 6.0% | SEK 84.50 | SEK 75.00 | SEK 39.90 | 2 |
| Nov ’23 | SEK 39.30 | SEK 79.75 +102.9% | 6.0% | SEK 84.50 | SEK 75.00 | SEK 32.60 | 2 |
| Oct ’23 | SEK 42.50 | SEK 114.50 +169.4% | 3.9% | SEK 119.00 | SEK 110.00 | SEK 32.70 | 2 |
| Sep ’23 | SEK 52.60 | SEK 114.50 +117.7% | 3.9% | SEK 119.00 | SEK 110.00 | SEK 37.00 | 2 |
| Aug ’23 | SEK 60.00 | SEK 114.50 +90.8% | 3.9% | SEK 119.00 | SEK 110.00 | SEK 43.50 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.